ArticleAPL bioengineering2025
Diffraction-informed deep learning for molecular-specific holograms of breast cancer cells.
Article in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lens-free digital in-line holography (LDIH) provides a large field-of-view at micrometer-scale resolution, making it a promising tool for high-throughput cellular analysis. However, the complexity of diffraction images (holograms) produced by LDIH presents challenges for human interpretation and requires time-consuming computational reconstruction, often leading to artifacts and information loss. To address these issues, we present HoloNet, a novel deep learning architecture specifically designed for direct analysis of diffraction images in cellular diagnostics. Tailored to the unique characteristics of diffraction images, HoloNet captures multi-scale features, enabling it to outperform conventional convolutional neural networks in recognizing well-defined regions within complex holograms. HoloNet classifies breast cancer cell types with high precision and quantifies molecular marker intensities using raw diffraction images of cells stained with ER/PR and HER2. Additionally, HoloNet has proven effective in transfer learning applications, accurately classifying breast cancer cell lines and discovering previously unidentified subtypes through unsupervised learning. By integrating computational imaging with deep learning, HoloNet offers a robust solution to the challenges of holographic data analysis, significantly improving the accuracy and explainability of cellular diagnostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.